Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Curcumin, the active compound in turmeric (Curcuma longa), is being investigated for its potential role in supporting or treating Chronic Obstructive Pulmonary Disease (COPD), primarily due to its anti-inflammatory and antioxidant properties. Preclinical studies (in vitro and animal models) have demonstrated that curcumin can inhibit pro-inflammatory cytokines, reduce oxidative stress, and modulate pathways such as NF-κB, which are implicated in the pathogenesis of COPD. Some small-scale human studies and pilot clinical trials have suggested that curcumin supplementation may reduce markers of inflammation and improve some measures of lung function in COPD patients. For example, limited trials have reported improvements in forced expiratory volume (FEV1) and reductions in circulating inflammatory markers after curcumin supplementation.

However, the clinical evidence is still preliminary and not robust. Most studies have small sample sizes, short durations, or lack rigorous controls. There is no consensus on effective dosing, and bioavailability of curcumin remains a challenge. Major clinical guidelines for COPD do not currently recommend curcumin as a standard therapy. While there is a scientific rationale and some early evidence suggesting benefit, current data are insufficient to firmly validate curcumin as an effective treatment for COPD. Therefore, the evidence rating is 2, reflecting promising but limited and inconclusive scientific support.

More about curcumin
More about Chronic Obstructive Pulmonary Disorder

Other ingredients used for Chronic Obstructive Pulmonary Disorder

Other health conditions supported by curcumin

Products containing curcumin

Nature's Sunshine Turmeric Curcumin (Formerly CurcuminBP)